A joint COVID-19 recovery proposal put forward by French President Emmanuel Macron and German Chancellor Angela Merkel on Monday (18 May) calls for a new European approach to health crises, aiming for greater EU sovereignty on medical products and pharmaceuticals.
Oxfam is urging governments and pharmaceutical companies to guarantee that vaccines, tests, and treatments will be patent-free and equitably distributed to all nations and people, ahead of the World Health Assembly next week.
How to ensure access for all to a coronavirus vaccine should be the priority for world leaders. Dr Bernard Pécoul offers five ideas leaders should consider this week as they aim to raise €7.5 billion to fund vaccine research.
The EU needs to focus on ways to bring the production of medicines and pharmaceutical ingredients back to Europe to avoid a future recurrence of shortages experienced during the COVID-19 crisis, the EU health boss Stella Kyriakides told MEPs on Tuesday (22 April).
After the coronavirus crisis is over, Europe will need policies that can create a research ecosystem in the long run as well as ensure access to medicines to the patients who need them in a way that is sustainable for health systems today and tomorrow, a leading representative of European pharmaceuticals told EURACTIV in an interview.
The President of the European Commission launched an EU-wide public consultation on Europe's Beating Cancer Plan on Tuesday (4 February), announcing an EU-wide "open health data space" in support of research, prevention and cure.
The EU health sector is in the middle of a defining moment but the sector is “up to a decade” behind other sectors in terms of digitalisation, Deputy Director-General for Health and Food Safety Martin Seychell told EURACTIV.com.
The new European Commission should tackle "head-on" rheumatic and musculoskeletal diseases, the president of the European League Against Rheumatism (Eular) told EURACTIV in an interview, referring to chronic diseases that affect one-quarter of all Europeans, creating healthcare and social security costs.
The much-awaited EU cancer plan will first have to identify specific needs at national level, seek funding and then be closely monitored in order to be successful, a high-ranking EU official has told EURACTIV.com.
In a fragmented EU market, the vaccines ecosystem is complex and in order for it to be “healthy” all relevant stakeholders should be taken into account, Professor Panos Kanavos, an associate professor at LSE, told EURACTIV.com.
Seven people have been diagnosed with measles in Zagreb in the past two weeks, raising concerns that more cases of this highly contagious virus may occur in light of the rising anti-vaccination campaigns.
With increased powers, Health Commissioner-designate Stella Kyriakides is tasked with striking a difficult balance between making sure there is a steady supply of affordable medicines and ensuring that EU pharma industry remains a world leader in innovation.
In art, Belgium is internationally recognised as the land of surrealism, where reality and dreams are intertwined to offer a new perspective on the world. Life sciences is another Belgian specialty and a major historical export product, a group of authors write.
The Czech government has launched a legislative initiative to improve access to most modern medications and rare disease drugs, Health Minister Adam Vojtěch told EURACTIV in an interview, adding that patients are involved in the decision-making process at a very early stage, including in drafting the law.
The next EU Commission should take a stronger position on innovation in the pharma sector, the new leader of the European Federation of Pharmaceutical Industries and Associations (EFPIA) told EURACTIV.com in an interview.
Every EU government should prioritise healthcare because only health citizens can be a driving force for economic growth, told EURACTIV Croatia Gabriele Grom, Vice President of MSD in Central Eastern Europe (CEE).
Stakeholders gathered in the European Public Health Alliance (EPHA) reiterated their demands to reform the incentives for pharmaceutical innovation, making a set of recommendations to the European Commission during an event in Brussels on Monday (3 June).
Europe could become the first region worldwide to incentivise the fight anti-microbial resistance (AMR), Nathalie Moll, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), told EURACTIV in an interview.
Medicine supplies and food safety standards are both vital and the EU cannot prioritise one over the other in the event of a no-deal Brexit, Vice President of the Commission Jyrki Katainen said on Thursday (4 April).
The EU pharma industry has prepared for a hard Brexit scenario but this is not enough as EU leaders need to take specific measures to ensure medical supplies after the UK departure, EU pharma chief Stefan Oschmann has said.
No decrease in resistance to antibiotics has been reported in the latest study drawn up by the EU's top two public health authorities, which should be a cause for alarm, according to the bloc's health boss, Vytenis Andriukaitis.
A number of pharma stakeholders announced on 9 February the official launch of the European Medicines Verification System (EMVS), which will make use of new technologies to improve safety in the medicines’ supply chain against fake products.
The industry of innovative medicines is concerned with a recent vote in the European Parliament on the stockpiling of generic drugs, saying that it causes uncertainty over innovation in the pharmaceutical field.